Date:11/15/2012

eutic monitoring of cardiovascular disease and related metabolic disorders – including pharmacogenomic and genetic tests. The company has adopted a unique clinical laboratory service model to provide physicians better diagnostic tools to help improve the cardiovascular health of their patients. The company is privately owned and funded by leading life science venture capital firms. Please visit www.aviir.com  for more information.

For media inquiries, please contact:
Dina Scaglione
Corporate Media Manager
949.910.9401

'/>"/>

SOURCE Aviir Inc. Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. Alzheimers Therapeutics Reviewed by NeuroPerspective
2. Peer-reviewed Article Reports ProImmune's Immune Formulation 200® Activates the Immune-Support Gene Nrf2.
3. Nucleic Acids Research Journal Publishes Sapphire Energy Peer-Reviewed Research Paper on a Chloroplast Genome From Green Algae
4. Karyopharm Therapeutics Announces Oral Presentation at the American College of Rheumatology (ACR) on the use of Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in preclinical models of Systemic Lupus Erythematosus (SLE)
5. Synthetic Biologics to Acquire Clinical-Stage C. difficile Infectious Disease Program
6. Apexigen Announces Initiation of Clinical Trials By Its Partner, Simcere Pharmaceutical Group
7. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Update and Reports Financial Results for Third Quarter 2012
8. Sanguine Appoints Darlene Rosario, Vice President of Regulatory Affairs & Quality at Biothera, Inc., to Clinical Advisory Board and Ethics Committee
9. Array BioPharma To Present Clinical Data At The 2012 ASH Meeting On ARRY-520, A KSP Inhibitor, And ARRY-614, A Dual p38/Tie2 Inhibitor
10. VolitionRxs Preliminary Diagnostic Clinical Trial Results Show High Sensitivity and Specificity for Colon, Breast and Lung Cancers
11. Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824